MyFinsight
Home
Blog
About
Net income
$237,007K
Accrued expenses and
other payables
$212,435K
Share-based compensation
expenses
$137,405K
Depreciation and
amortization expense
$40,515K
Accounts payable
$37,530K
Acquired in-process
research and development
$20,518K
Net cash provided by
operating activities
$462,820K
Effect of foreign
exchange rate changes,...
$19,836K
Canceled cashflow
$209,734K
Net increase in
cash, cash...
$427,249K
Canceled cashflow
$55,407K
Accounts receivable
$117,576K
Inventories
$47,150K
Amortization of research and
development cost share...
-$29,518K
Other assets
$11,377K
Other liabilities
-$4,113K
Proceeds from sale or
maturity of investments
$5,845K
Proceeds from option
exercises and employee...
$11,048K
Repayment of sale of future
royalties liability
-$1K
Net cash used in
investing activities
-$49,353K
Net cash provided by
financing activities
-$6,054K
Canceled cashflow
$5,845K
Canceled cashflow
$11,049K
Purchases of property,
plant and equipment
$27,476K
Purchase of in-process
research and development
$20,518K
Other investing
activities
$7,204K
Repayment of long-term
loan
$17,052K
Other financing
activities
-$51K
Back
Back
Cash Flow
BeOne Medicines Ltd. (ONC)
BeOne Medicines Ltd. (ONC)
source: myfinsight.com